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Abstract Insulin-like growth factor binding protein-6 binds
insulin-like growth factor-II with a marked preferential affinity
over insulin-like growth factor-I. The kinetic basis of this binding
preference was studied using surface plasmon resonance. Binding
of insulin-like growth factor-I and insulin-like growth factor-II to
immobilized insulin-like growth factor binding protein-6 fitted a
two-site binding kinetic model. Insulin-like growth factor-I and
insulin-like growth factor-II association rates were similar
whereas the dissociation rate was V60-fold lower for insulin-
like growth factor-II, resulting in a higher equilibrium binding
affinity for insulin-like growth factor-II. The equilibrium binding
affinities of a series of insulin-like growth factor-II mutants were
also explained by differential dissociation kinetics. O-glycosyla-
tion had a small effect on the association kinetics of insulin-like
growth factor binding protein-6. The insulin-like growth factor
binding properties of insulin-like growth factor binding protein-6
are explained by differential dissociation kinetics.
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1. Introduction
Insulin-like growth factors (IGF-I and IGF-II) are impor-
tant mediators of physiological growth [1]. Their actions are
modulated by a family of six structurally related, high a⁄nity
binding proteins (IGFBPs 1^6), which may enhance or inhibit
IGF actions under di¡erent conditions [1,2]. IGFBP-6 has the
highest binding a⁄nity of the IGFBPs for IGF-II [1,2]. It
di¡ers from the other IGFBPs in that it binds IGF-II with
a 20^100-fold higher a⁄nity than IGF-I [3^7]. IGFBP-6 is
therefore a relatively speci¢c inhibitor of IGF-II actions
[6,8,9]. However, the kinetic basis of the IGF-II binding pref-
erence of IGFBP-6 has not been previously studied.
Surface plasmon resonance (SPR) technology allows real-
time measurement of binding between a ligand in solution
which is passed over a sensor chip to which an interacting
molecule is immobilized [10]. Using this technology, both as-
sociation and dissociation kinetics can be determined. The
kinetics of IGF binding to IGFBPs other than IGFBP-6
have been previously determined by SPR [11^14] and some
of these studies suggested two-site binding kinetics [11,12].
IGFBP-3 had high and low a⁄nity binding sites for IGFs,
where the high a⁄nity site accounted for 90% of IGF binding
[11]. Binding of IGFBP-2 to immobilized IGF-II ¢tted a two-
site model, with two association and two dissociation rates
[12]. In contrast, IGFBP-2 bound immobilized IGF-I with
single-site association and dual-site dissociation kinetics.
These ¢ndings suggest a more complex interaction between
IGFs and IGFBPs than previously believed.
In this study, SPR was used to investigate the kinetic basis
for the binding preference of IGFBP-6 for IGF-II over IGF-I.
Kinetics of binding of IGF-II mutants with decreased binding
a⁄nities for IGFBP-6 [7] were also studied. Further, IGFBP-6
is O-glycosylated and we have previously shown that enzy-
matic deglycosylation of IGFBP-6 had no e¡ect on the IGF
binding, measured by solution competition studies with
[125I]IGF-II [15]. The role of O-glycosylation of IGFBP-6
was further studied by comparing the kinetics of IGF binding
to glycosylated and non-glycosylated IGFBP-6.
2. Materials and methods
2.1. IGFBPs
Recombinant human glycosylated IGFBP-6 (gIGFBP-6) was ex-
pressed in A293 kidney ¢broblasts stably transfected with the mam-
malian expression vector, phBP6-E3 [8], using lipofectamine (Life
Technologies, Glen Waverley, Australia) [16]. gIGFBP-6 was puri¢ed
to homogeneity by IGF-II a⁄nity chromatography and reverse-phase
FPLC as previously described [16,17]. The identity and purity of
gIGFBP-6 were con¢rmed by N-terminal Edman sequencing.
Non-glycosylated IGFBP-6 (n-gIGFBP-6) was expressed as a solu-
ble GST fusion protein in Escherichia coli transformed with pGex-2T
(Pharmacia, Piscataway, NJ, USA) [17]. The fusion protein was
bound to a glutathione-agarose column and n-gIGFBP-6 was cleaved
from the column with thrombin. n-gIGFBP-6 was further puri¢ed by
IGF-II a⁄nity chromatography and reverse-phase FPLC. Identity
and purity were con¢rmed by electrospray ionization mass spectrom-
etry as previously described [17].
2.2. SPR analysis of interactions between IGFs and IGFBP-6
SPR analysis was performed using the BIAcore 2000 system (BIA-
core AB, Uppsala, Sweden). gIGFBP-6 and n-gIGFBP-6 were immo-
bilized by amine coupling onto separate channels on a CM5 sensor
chip (BIAcore AB) as described below. The geometry of the CM5
sensor chip allows the same IGF sample in solution to sequentially
£ow over each IGFBP preparation and a control channel, to which no
IGFBP was immobilized. The control channel was included to meas-
ure di¡erences in the bulk refractive index due to changes in bu¡ers.
Prior to immobilization of IGFBP-6, the carboxy-methylated dex-
tran surface of the CM5 chip was activated by exposure to equal
volumes of 0.39 M N-ethyl-NP-(3-diethyl-aminopropyl) carbodiimide
and 0.1 M N-hydroxysuccinimide. gIGFBP-6 or n-gIGFBP-6 (10 Wg/
ml) in HBS bu¡er (0.01 M HEPES, pH 7.4, 0.15 M NaCl, 0.005% P20
detergent) or HBS bu¡er alone (control) were injected onto separate
channels of the activated surface (10 Wl/min, 20‡C). Residual active
coupling groups were inactivated by exposure to 1 M ethanolamine.
Following immobilization, the chip was washed for 30 min with HBS
bu¡er. The net increase in the signal (682 and 1642 resonance unit
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(RU) of gIGFBP-6 and n-gIGFBP-6, respectively, where 1000 RU is
approximately equivalent to 1 ng of protein/mm2) represents the
amount of immobilized protein.
IGF-I and IGF-II (1.31^134 nM, kind gifts from Lilly, Indianap-
olis, IN, USA) in HBS were passed over the chip at 10 Wl/min for
10 min (n = 4 for each IGF). A series of IGF-II mutants ([R54,
R55]IGF-II, [L27]IGF-II and [T48, S49, I50]IGF-II, generously provided
by Dr K. Sakano (Daiichi Pharmaceuticals, Tokyo, Japan)) with dif-
ferential binding a⁄nities for IGFBPs as measured by a solution
competition assay [7] was also studied as above (n = 2 for each mu-
tant). Following injection of each of the IGFs, the kinetics of disso-
ciation were evaluated by passing HBS bu¡er alone over the chip at
10 Wl/min for 10 min. After each run, the chip was regenerated with
0.01 M HCl to elute the remaining bound IGFs. All experiments were
performed at 20‡C.
Similar binding kinetics were observed at £ow rates of 20 Wl/min
and 50 Wl/min (results not shown), suggesting minimal e¡ects of mass
transport limitation on binding of IGFs to IGFBPs [10].
2.3. Data analysis
Kinetic constants were derived using BIAevaluation software ver-
sion 2.1 (BIAcore AB). All binding curves were corrected for back-
ground by the subtraction of the signal obtained from the control
channel. Apparent kinetic constants were generated by ¢tting both
the experimental association and dissociation curves separately to
either a one-site and two-site model. Experimental data for each lig-
and best-¢tted a two-site model. The relative contribution of each
binding site to the total binding was calculated and is described as
a weighting factor. Data are shown as mean þ S.E.M. of four runs for
IGF-I and IGF-II and two runs for the IGF-II analogues.
Equilibrium association constants (Ka) were calculated using the
weighted average of the two association rates (konapp) as described
by Hobba et al. [12]. The contribution of the second dissociation rate
(koff2) to the total dissociation was always less than 15% and therefore
did not substantially a¡ect the total dissociation. The equilibrium
association constant was therefore de¢ned as konapp/koff1 [12].
2.4. Solution assays
Competitive binding studies were carried out as previously de-
scribed [7]. IGFBPs were incubated with [125I]IGF-II (2U104 cpm,
speci¢c activity 168 WCi/Wg) þ unlabelled IGF-I (0.0013^10.5 nM),
IGF-II (0.0067^10.3 nM) or IGF-II mutants (0.001^11 nM) for
18 h at 4‡C in 0.1 M NaPO4/0.1% bovine serum albumin (BSA)/
0.02% Na azide (pH 7.4). Free tracer was removed by incubation
with ice-cold 5% charcoal, 2% BSA in Dulbecco’s phosphate bu¡ered
saline, followed by centrifugation and counting of bound radioactivity
in the supernatant. Points were measured in duplicate. IGF binding
a⁄nities were determined using Prism software (GraphPad, San Die-
go, CA, USA).
3. Results
3.1. Dissociation kinetics explain the IGF-II binding preference
of IGFBP-6
Previous studies using solution binding assays have shown
that IGFBP-6 has a 20^100-fold preferential binding a⁄nity
for IGF-II over IGF-I [3^7]. Similarly, gIGFBP-6 bound
IGF-II with a 67-fold IGF-II binding preference as assessed
Fig. 1. Sensorgrams of IGF-II (A, C) and IGF-I binding (B, D) to glycosylated (A, B) and non-glycosylated IGFBP-6 (C, D). IGF-II (1.34,
2.68, 6.69, 13.4, 26.8, 53.5, 107 and 134 nM from bottom to top curve) or IGF-I (1.31, 2.61, 6.54, 13.1, 26.1, 52.3, 105 and 131 nM from bot-
tom to top curve) were passed over immobilized IGFBP-6 for 10 min (association phase). The bu¡er £ow was then switched to HBS for 10 min
(dissociation phase). Sensorgrams were normalized so that maximal binding of IGF-II to g or n-gIGFBP-6 was set to 100%. Maximal binding
was 140 RU and 410 RU for gIGFBP-6 and n-gIGFBP-6, respectively. Results have been corrected for refractive index changes due to bu¡er
change-over.
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by SPR analysis (Table 1). Typical sensorgrams for IGF bind-
ing to gIGFBP-6 are shown in Fig. 1.
The IGF binding kinetics of gIGFBP-6 best-¢tted a two-site
model. For both IGF-I and IGF-II, V70% of the total asso-
ciation was due to the rapid association component (Table 1).
The weighted association rates (konapp) for binding of IGF-I
and IGF-II to gIGFBP-6 were similar (Table 1). The di¡er-
ence in the equilibrium binding a⁄nities of IGF-I and IGF-II
for gIGFBP-6 was due to di¡ering dissociation rates. The
major dissociation rate (koff1) was V60-fold higher for IGF-
I than IGF-II (Table 1). Although the minor dissociation rate
(koff2) was 10-fold lower for IGF-I than IGF-II, this ac-
counted for less than 15% of the total dissociation.
Fig. 2 shows a typical sensorgram for binding of IGF-II
and IGF-II mutants, [L27]IGF-II, [R54, R55]IGF-II and [T48,
S49, I50]IGF-II, to IGFBP-6. The A-domain mutant, [R54,
R55]IGF-II, has previously been shown to have a V5-fold
lower binding a⁄nity than IGF-II for IGFBP-6 using solution
assays [7]. The B-domain mutant, [L27]IGF-II, has a V3-fold
reduced binding a⁄nity for IGFBP-6 [7], whereas [T48, S49,
I50]IGF-II does not substantially bind to IGFBP-6 [7]. Using
SPR, the order of maximal binding was IGF-IIs [R54,
R55]IGF-IIs [L27]IGF-IIs [T48, S49, I50]IGF-II. Although
the rapid association constant for [T48, S49, I50]IGF-II was
3-fold higher than that of IGF-II, it only accounted for 33%
of the total association compared with 62^85% for IGF-I,
IGF-II and other mutants (Table 1). The weighted apparent
association rates of the three IGF-II mutants were similar to
or slightly greater than that of IGF-II (Table 1). However, the
equilibrium binding constants for all three mutants were lower
than that of IGF-II because of a more rapid dissociation
(Table 1). This was especially apparent for [T48, S49,
I50]IGF-II which had dissociation kinetics similar to those
of IGF-I. Similarly to IGF-I, the di¡erential binding a⁄nities
of IGF-II mutants for gIGFBP-6 are therefore determined by
di¡erential dissociation rates.
Table 1
Binding kinetics of glycosylated IGFBP-6
kon1U105
(M31/s)
kon2U105
(M31/s)
konappU105
(M31/s)
Weighting
factora
Koff1U1033
(s31)
koff2U1033
(s31)
KA (nM31)b Relative a⁄nity
(% of IGF-II)
IGF-I 8.9 þ 1.3 0.30 þ 0.04 5.6 þ 0.8 0.62 20.3 þ 0.8 1.1 þ 0.1 0.028 þ 0.003 1.5
IGF-II 9.3 þ 0.4 0.31 þ 0.00 6.3 þ 0.3 0.67 0.34 þ 0.01 11.6 þ 0.1 1.88 þ 0.16 100
[R54, R55]IGF-II 13.6 þ 2.5 1.3 þ 0.2 11.3 þ 1.7 0.82 0.90 þ 0.20 15.6 þ 0.4 1.29 þ 0.08 69
[L27]IGF-II 9.2 þ 0.8 1.0 þ 0.2 8.0 þ 0.6 0.85 0.94 þ 0.01 13.8 þ 0.6 0.85 þ 0.08 45
[T48, S49, I50]IGF-II 29.7 þ 1.0 0.72 þ 0.01 10.1 þ 2.6 0.33 11.9 þ 3.9 0.2 þ 0.1 0.085 þ 0.006 4.5
aWeighting factor indicated the proportion of total binding due to kon1 (where total binding = 1).
bKA = konapp/koff1 since koff2 contributed less than 15% to the total dissociation in all instances.
Fig. 2. Sensorgrams of binding of IGF-II and IGF-II mutants to
IGFBP-6. Shown are normalized sensorgrams for the interaction of
gIGFBP-6 (A) and n-gIGFBP-6 (B) with 50 nM of (i) IGF-II, (ii)
[R54, R55]IGF-II, (iii) [L27]IGF-II and (iv) [T48, S49, I50]IGF-II. Sen-
sorgrams were normalized so that maximal binding of IGF-II to g
or n-gIGFBP-6 was set to 100%. Maximal binding was 120 RU and
350 RU for gIGFBP-6 and n-gIGFBP-6, respectively. Results have
been corrected for refractive index changes due to bu¡er change-
over.
Fig. 3. A charcoal adsorption competition assay of IGF binding by
glycosylated and non-glycosylated IGFBP-6. gIGFBP-6 (closed) and
n-gIGFBP-6 (open) were incubated with [125I]IGF-II (3U104 cpm/
well) þ unlabelled IGF-II (circles), IGF-I (square), [R54, R55]IGF-II
(triangles), [L27]IGF-II (inverted triangles) or [T48, S49, I50]IGF-II
(diamonds). Results are shown as a percentage of speci¢c binding in
the absence of unlabelled IGF-II (% B/Bo). Total speci¢c binding
(Bo) was 12.6% and 11.7% of the total counts for gIGFBP-6 and n-
gIGFBP-6, respectively. Duplicate measurements for each point dif-
fered by less than 5%. Non-speci¢c binding was 5.8%.
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3.2. O-glycosylation modestly increases the association kinetics
of IGF-II binding to IGFBP-6
To con¢rm that n-gIGFBP-6 expressed in E. coli was cor-
rectly folded, the stoichiometry of high a⁄nity IGF-II binding
to gIGFBP-6 and n-gIGFBP-6 was compared. The stoichiom-
etry of IGF:IGFBP-6 binding in solution is V1:1 [4]. Assum-
ing the same stoichiometry, V80% of the expected binding of
IGF-II to both gIGFBP-6 and n-gIGFBP-6 was experimen-
tally observed. This result con¢rms the correct folding of n-
gIGFBP-6 since it is likely to be required for high a⁄nity
binding. Further, this result indicates that immobilization of
IGFBP-6 to the sensor chip surface did not substantially im-
pair binding.
The association kinetics of IGF-I binding to n-gIGFBP-6
and gIGFBP-6 were similar (Fig. 1, Table 1 and 2). In con-
trast, the konapp of IGF-II binding to n-gIGFBP-6 was V3-
fold lower than that of gIGFBP-6 (Table 1 and 2). The dis-
sociation kinetics of IGF binding to n-gIGFBP-6 were similar
to those of gIGFBP-6 (Table 1 and 2). Because of the lower
association rate of IGF-II binding to n-gIGFBP-6, the equi-
librium association constant was alsoV3-fold lower than that
of gIGFBP-6 and the IGF-II binding preference of n-
gIGFBP-6 over IGF-I was reduced to 24-fold.
Similarly to IGF-II, the association rates of IGF-II mutant
binding to n-gIGFBP-6 were 3^7-fold lower than those of
gIGFBP-6 whereas the dissociation rates were similar.
Although the equilibrium a⁄nity constants were therefore
modestly lower for n-g than gIGFBP-6, the relative binding
a⁄nities of the IGF-II mutants and IGF-II were similar for
both IGFBP-6 preparations.
3.3. Solution competition assay of IGF binding to gIGFBP-6
and n-gIGFBP-6
The results obtained using SPR were compared with com-
petition solution assays using [125I]IGF-II as tracer and the
same IGF preparations used for the SPR studies (Fig. 3). The
binding a⁄nity of gIGFBP-6 for IGF-II was V8-fold higher
when measured by a charcoal binding assay compared with
SPR (Table 3). Although charcoal assays were performed at
4‡C and SPR at 20‡C, the binding a⁄nity of IGFBP-6 for
IGF-II was unchanged when measured by the charcoal assay
at 20‡C (not shown), indicating that the temperature di¡er-
ence did not underlie the binding a⁄nity di¡erence.
Similarly to previous studies [3^7], IGF-I bound to
gIGFBP-6 with V25-fold lower a⁄nity than IGF-II.
[L27]IGF-II and [R54, R55]IGF-II had 3^5-fold lower binding
a⁄nities for gIGFBP-6 than IGF-II, whereas [T48, S49,
I50]IGF-II did not bind to gIGFBP-6, which is consistent
with our previous studies [7].
We have previously shown that enzymatic deglycosylation
of IGFBP-6 did not a¡ect IGF binding a⁄nities when using
[125I]IGF-II as tracer in solution assays [15]. The lack of e¡ect
of O-glycosylation on IGF binding by IGFBP-6 using solu-
tion assays was con¢rmed in the present study (Fig. 3). The
relative binding a⁄nities of IGF-II mutants for n-gIGFBP-6
were similar to those for gIGFBP-6 (Table 3).
4. Discussion
Using SPR, the results of the present study show that the
preferential binding a⁄nity of IGFBP-6 for IGF-II over IGF-
I is a result of the lower dissociation rate of IGF-II. Similarly,
di¡erential dissociation rates determined the binding a⁄nities
of IGF-II mutants. This suggests that, whereas association of
IGFs with IGFBP-6 is relatively independent of small changes
in the IGF sequence, dissociation is determined by speci¢c
amino acids in the IGF sequences. This is exempli¢ed by
the IGF-II analogue [T48, S49, I50]IGF-II, the association
rate of which was slightly higher than that of IGF-II, but
which dissociated far more rapidly. In contrast to the present
¢ndings regarding IGFBP-6, di¡erences in both association
and dissociation rates accounted for the decreased binding
a⁄nities of IGF-I mutants for IGFBP-1 and the IGF-I recep-
tor [13,18] and IGFBP-3 [11].
Signi¢cant alteration of high a⁄nity ligand binding is a
relatively uncommon consequence of protein glycosylation
[19]. O-glycosylation slightly a¡ected the binding of IGF-II
and IGF-II mutants but not IGF-I to IGFBP-6 as assessed
Table 2
Binding kinetics of non-glycosylated IGFBP-6
kon1U105
(M31/s)
kon2U105
(M31/s)
konappU105
(M31/s)
Weighting
factora
Koff1U1033
(s31)
koff2U1033
(s31)
KA (nM31)b Relative a⁄nity
(% of IGF-II)
IGF-I 6.5 þ 0.1 0.31 þ 0.03 4.6 þ 0.1 0.67 19.7 þ 0.0 1.3 þ 0.1 0.023 þ 0.001 4.2
IGF-II 2.8 þ 0.0 0.18 þ 0.00 2.0 þ 0.0 0.70 0.36 þ 0.01 10.6 þ 0.1 0.55 þ 0.01 100
[R54, R55]IGF-II 3.5 þ 2.4 0.3 þ 0.03 2.9 þ 1.5 0.80 0.68 þ 0.04 12.6 þ 1.4 0.43 þ 0.2 78
[L27]IGF-II 1.2 þ 0.1 0.6 þ 0.05 1.1 þ 0.5 0.82 0.92 þ 0.01 14.4 þ 1.7 0.12 þ 0.05 22
[T48, S49, I50]IGF-II 12.4 þ 4.3 0.42 þ 0.04 3.6 þ 0.3 0.28 15.8 þ 2.0 0.4 þ 0.1 0.022 þ 0.001 4.0
aWeighting factor indicated the proportion of total binding due to kon1 (where total binding = 1).
bKA = konapp/koff1 since koff2 contributed less than 15% to the total dissociation in all instances.
Table 3
Comparison of IGF binding a⁄nities for IGFBP-6 using a solution binding assay and SPR
Glycosylated IGFBP-6 Non-glycosylated IGFBP-6
Solution (nM31) SPR (nM31) Solution (nM31) SPR (nM31)
IGF-II 14.1 þ 0.1 1.88 þ 0.16 12.5 þ 0.1 0.55 þ 0.01
IGF-I 3% 1.5% 5% 4%
[R54, R55]IGF-II 22% 69% 17% 78%
[L27]IGF-II 30% 45% 30% 22%
[T48, S49, I50]IGF-II 0% 5% 0% 4%
Binding a⁄nities of IGF-I and IGF-II mutants are shown as a percentage of IGF-II.
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by SPR. Association rates and therefore equilibrium binding
a⁄nities of IGF-II and mutants were 3^6-fold lower for n-
gIGFBP-6 than gIGFBP-6. In contrast, dissociation rates
were similar for n-gIGFBP-6 and gIGFBP-6. However,
IGF-II binding a⁄nities measured with charcoal assays were
similar for both gIGFBP-6 and n-gIGFBP-6 performed at
either 4‡C or 20‡C. It is possible that more subtle changes
in binding are detectable by SPR because of its inherent sen-
sitivity. These subtle changes may also be missed in solution
assays due to the need for iodinated ligand, which may have
slightly altered binding properties. Alternatively, immobiliza-
tion of gIGFBP-6 and n-gIGFBP-6 to the sensor chip surface
may have resulted in slightly di¡erent availabilities of IGF-II
binding sites on each.
The binding a⁄nity of gIGFBP-6 measured by SPR was
8-fold lower than that measured by a solution binding assay.
The di¡erence in binding a⁄nity cannot be explained by the
SPR and solution experiments being performed at di¡erent
temperatures, since the binding a⁄nity of IGFBP-6 was un-
a¡ected by temperature using solution assays. However, it has
previously been shown that the association rates of some lig-
and binding protein interactions are lower when measured by
SPR than in solution [10].
The sensitivity of SPR allowed low a⁄nity binding of
IGFBP-6 by the IGF-II mutant [T48, S49, I50]IGF-II to be
detected. As previously reported [7], no binding of this mutant
was detected by a charcoal assay. Insulin was shown to bind
with low a⁄nity to IGFBP-3 using SPR [11], despite its in-
ability to compete with iodinated IGFs for binding to IGFBPs
using solution assays. These ¢ndings suggest that SPR is a
superior method for the detection of low a⁄nity binding.
However, IGF-I binding to IGFBP-6 is readily detectable in
solution assays despite having a similar low binding a⁄nity to
[T48, S49, I50]IGF-II for IGFBP-6 using SPR. Other as yet
unexplained factors must also underlie these observations.
IGF bound to IGFBP-6 with two-site kinetics in the present
study. It is not clear whether this indicates two distinct phys-
ical binding sites for IGFs on IGFBP-6 or complex binding
kinetics on a single physical site. It is noteworthy that com-
petition curves for binding to IGFBP-6 of unlabelled IGF-I
and IGF-II are not parallel when [125I]IGF-I is used as a
tracer and the presence of high and low a⁄nity binding sites
on IGFBP-6 has previously been suggested on this basis [3,6].
However, the V1:1 stoichiometry of binding would suggest
that IGFs do not simultaneously bind at two sites on IGFBP-
6. An alternative possibility is that the presence of a second
low a⁄nity site may be a SPR artefact due to IGFBP-6 being
randomly linked to the sensor chip by amine coupling, with
subsequent impairment of IGF binding of a proportion of the
linked molecules. This is unlikely, however, since (i) the
IGFBP-6 stoichiometry was V0.8 for IGF-II (approximating
1:1 binding), (ii) the contribution of the second association
site in IGFBP-6 (30^40%) was greater than that observed for
IGFBP-3 (V10%) [11] and is greater than would be expected
for an amine coupling e¡ect, (iii) a previous study in which
IGFs were immobilized to the sensor chip and bound by
soluble IGFBP-2 also suggested two-site kinetics [12]. Artefac-
tual multiple-site binding using SPR may be due to mass
transport e¡ects limiting the ligand delivery to the sensor sur-
face. However, this is unlikely because the binding kinetics of
IGFBP-6 were una¡ected by the £ow rate.
In conclusion, the binding preference of IGFBP-6 for IGF-
II over IGF-I is due to a slower dissociation of IGF-II rather
than a more rapid association. O-glycosylation of IGFBP-6
modestly increases association kinetics without a¡ecting the
dissociation. SPR enables the detection of low a⁄nity binding
of some IGF-II mutants to IGFBP-6 which is not detectable
by competitive binding studies in solution. SPR analysis of
IGF binding to IGFBP-6 indicates dual-site kinetics. Further
studies are necessary to determine whether this re£ects two
distinct binding sites or complex interactions such as multi-
ple-step binding at a single-site.
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